Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diabetic retinopathy
Biotech
Boehringer inks another eye disease deal, this time with Palatin
Boehringer has inked a deal with Palatin Technologies worth up to $327 million biobucks to develop new retinal disease therapies.
Gabrielle Masson
Aug 18, 2025 10:30am
Valo abandons ROCK inhibitor after diabetic retinopathy fail
Jan 2, 2025 9:43am
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
Mar 14, 2024 9:15am
Roche drops oral eye disease drug after completing phase 2
Oct 19, 2023 5:50am
Ocuphire's diabetic eye drug misses phase 2 primary endpoint
Jan 26, 2023 8:32am
Eye AI? Aye-aye, FDA tells AEYE
Nov 17, 2022 10:26am
